Enovis (ENOV) to Release Earnings on Wednesday

Enovis (NYSE:ENOV - Get Free Report) is set to issue its quarterly earnings data before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.63 per share for the quarter. Enovis has set its FY24 guidance at $2.62-$2.77 EPS and its FY 2024 guidance at 2.620-2.770 EPS.Persons interested in listening to the company's earnings conference call can do so using this link.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.03. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The company had revenue of $525.20 million during the quarter, compared to the consensus estimate of $525.99 million. During the same quarter in the prior year, the company earned $0.61 earnings per share. The firm's revenue for the quarter was up 22.6% on a year-over-year basis. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Stock Up 3.9 %

Shares of NYSE ENOV traded up $1.56 during trading on Wednesday, reaching $42.07. The company had a trading volume of 1,195,459 shares, compared to its average volume of 569,139. Enovis has a 12-month low of $38.27 and a 12-month high of $65.03. The stock has a market cap of $2.35 billion, a PE ratio of -25.78 and a beta of 1.91. The business's 50-day moving average is $42.43 and its 200 day moving average is $46.10. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40.

Analyst Upgrades and Downgrades

ENOV has been the topic of several recent analyst reports. JMP Securities assumed coverage on Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price objective on the stock. Evercore ISI decreased their price objective on Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 1st. JPMorgan Chase & Co. decreased their price objective on Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a research note on Thursday, August 8th. Finally, Needham & Company LLC decreased their price objective on Enovis from $82.00 to $65.00 and set a "buy" rating on the stock in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $67.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.